Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial.

Tanabe, K; Serruys, P; Degertekin, M; Grube, E; Guagliumi, G; Urbaszek, W; Bonnier, J; Lablanche, J; Siminiak, T; Nordrehaug, J; Figulla, H; Drzewiecki, J; Banning, A; Hauptmann, K; Dudek, D; Bruining, N; Hamers, R; Hoye, A; Ligthart, J; Disco, C; Koglin, J; Russell, M; Colombo, A

Journal article

Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial.

Abstract:: BACKGROUND: The clinical impact of late incomplete stent apposition (ISA) for drug-eluting stents is unknown. We sought to prospectively investigate the incidence and extent of ISA after the procedure and at 6-month follow-up of paclitaxel-eluting stents in comparison with bare metal stents (BMS) and survey the clinical significance of ISA over a period of 12 months. METHODS AND RESULTS: TAXUS II was a randomized, double-blind study with 536 patients in 2 consecutive cohorts comparing slow-release (SR; 131 patients) and moderate-release (MR; 135 patients) paclitaxel-eluting stents with BMS (270 patients). This intravascular ultrasound (IVUS) substudy included patients who underwent serial IVUS examination after the procedure and at 6 months (BMS, 240 patients; SR, 113; MR, 116). The qualitative and quantitative analyses of ISA were performed by an independent, blinded core laboratory. More than half of the instances of ISA observed after the procedure resolved at 6 months in all groups. No difference in the incidence of late-acquired ISA was observed among the 3 groups (BMS, 5.4%; SR, 8.0%; MR, 9.5%; P=0.306), with a similar ISA volume (BMS, 11.4 mm3; SR, 21.7 mm3; MR, 8.5 mm3; P=0.18). Late-acquired ISA was the result of an increase of vessel area without change in plaque behind the stent. Predictive factors of late-acquired ISA were lesion length, unstable angina, and absence of diabetes. No stent thrombosis occurred in the patients diagnosed with ISA over a period of 12 months. CONCLUSIONS: The incidence and extent of late-acquired ISA are comparable in paclitaxel-eluting stents and BMS. ISA is a pure IVUS finding without clinical repercussions.

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Tanabe, K., Serruys, P., Degertekin, M., Grube, E., Guagliumi, G., Urbaszek, W., Bonnier, J., Lablanche, J., Siminiak, T., Nordrehaug, J., Figulla, H., Drzewiecki, J., Banning, A., Hauptmann, K., Dudek, D., Bruining, N., Hamers, R., Hoye, A., Ligthart, J., … Colombo, A. (2005). Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation, 111(7), 900–905.

MLA Style

Tanabe, K, et al. “Incomplete Stent Apposition after Implantation of Paclitaxel-Eluting Stents or Bare Metal Stents: Insights from the Randomized TAXUS II Trial.” Circulation, vol. 111, no. 7, 2005, pp. 900–05.

Chicago Style

Tanabe, K, P Serruys, M Degertekin, et al. 2005. “Incomplete Stent Apposition after Implantation of Paclitaxel-Eluting Stents or Bare Metal Stents: Insights from the Randomized TAXUS II Trial.” Circulation 111 (7): 900–905.
Print